ALGS News & Events

Hardean Achneck, MD resigned from his position as Executive Vice President, Chief Medical Officer.

Aligos Therapeutics announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus, HBV, infection. The first protocol defined interim analysis includes approximately 60% HBeAg- participants that complete 12 weeks of the treatment period. This enrollment milestone occurred in Q4 2025. In addition, the planned enrollment of this cohort of 60 HBeAg- participants completed in January 2026. The first interim analysis is expected to occur in the first half of 2026. A second protocol defined interim analysis is planned when approximately 50% HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026. This interim analysis is expected to occur in the second half of 2026.

Aligos Therapeutics announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer. Hassard will lead and build the Company's global commercial capabilities and serve as a member of Aligos' Senior Leadership Team. Prior to joining Aligos, Jim was CCO at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals.